Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Eurofins Scientific SE (ERF.PA)
EUR69.30
+0.30 (+0.43%)
LU PAR Healthcare Medical - Diagnostics & Research
Address
23 Val Fleuri 1526
Luxembourg, LU, LU
Luxembourg, LU, LU
CEO
Gilles Martin
Website
eurofins.com
IPO
1997-10-24
ISIN FR0014000MR3
Also trades on
Euronext Paris · ERF.PA (EUR)
Other OTC · ERFSF (USD)
Vienna Stock Exchange · ESF.VI (EUR)
Description
Eurofins Scientific SE, together with its subsidiaries, provides various analytical testing and laboratory services worldwide. It provides services, such as agroscience, including biological assessment, consumer and human, environmental safety, product chemistry, regulatory consultancy, and seed services; agro testing; assurance, including sustainability, audit, certification, quality inspection, QA-QC programme, and food and dietary supplement labelling services; biopharma, and clinical diagnostics. The company also offers consumer product testing, which include sustainability, testing, certifications and approvals, expert services and regulatory, inspections, audits, consumer research and sensory evaluation, and training courses; cosmetics and personal care; and electrical and electronics laboratories services. In addition, it provides environment testing, including maritime, water, air, soil, building material, pollution, waste, fuel/oil, microplastics, and radioactivity testing; and food and feed testing that include allergen, audit and certification, authenticity, carbohydrates, consulting, dioxins and POPs, food irradiation, GMO, heavy metal, melamine, microbiology, molecular biology, mycotoxin, nutritional analyses, organic contaminants, pesticide, veterinary drug, vitamin, and residual DNA testing. Further, the company provides forensic, genomic, maritime, materials and engineering, REACH, and sensory and consumer services, as well as in vitro diagnostics and PSS insourcing solutions. The company was founded in 1987 and is headquartered in Luxembourg, Luxembourg.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
EUR69.30
+0.30 (+0.43%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
326.6K
Beta
0.86
Float Shares
112.89M
Free Float %
64.6%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +1.13% | -0.86% | +5.83% | -8.36% | +6.51% | +0.10% | +6.33% | +1.79% | -29.24% | +80.73% | +3,240.11% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
69.30
DCF (Unlevered)
72.08
+4.0%
DCF (Levered)
79.70
+15.0%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
40% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 2 | 0 |
| Buy | 4 | 0 |
| Hold | 7 | 0 |
| Sell | 1 | 0 |
| Strong Sell | 1 | +1 |
Quality scores
Altman Z-Score
3.00
Safe zone
Piotroski F-Score
7 / 9
Strong
MOAT Score
5 / 10
Developing
Composite Rating
B
Overall Score
3 / 5
Medium
DCF Score
4 / 5
High
ROE Score
4 / 5
High
ROA Score
4 / 5
High
D/E Score
1 / 5
Low
P/E Score
2 / 5
Medium
P/Book Score
2 / 5
Medium
Operational MOAT
✗ Below peers
-
Revenue growth Medical - Diagnostics & Research: +7.9%+5.0% Q4'25: +11.5% (vs Q4'23)
-
EPS growth Medical - Diagnostics & Research: +30.8%+21.5% Q4'25: +53.8% (vs Q4'23)
-
FCF margin FCF growth · Medical - Diagnostics & Research: +32.2%+7.2% Q4'25: +6.8% (vs Q4'23)
-
EBIT margin Medical - Diagnostics & Research: +9.6%+11.2% ★ Q4'25: +11.4% (vs Q4'23)
-
ROIC Medical - Diagnostics & Research: +5.2%+7.2% ★ Q4'25: +15.0% (vs Q4'23)
-
Share dilution Medical - Diagnostics & Research: 0.0%-3.9% ★ Q4'25: -5.4% (vs Q4'23)
-
Debt / EBITDA Net debt/EBITDA · Medical - Diagnostics & Research: -0.13×3.75× Q4'25: 1.96× (vs Q4'23)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2000 actual |
Dec 2001 actual |
Dec 2002 actual |
Dec 2003 actual |
Dec 2004 actual |
Dec 2005 actual |
Dec 2006 actual |
Dec 2007 actual |
Dec 2008 actual |
Dec 2009 actual |
Dec 2010 actual |
Dec 2011 actual |
Dec 2012 actual |
Dec 2013 actual |
Dec 2014 actual |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 11 Rev. Ana. 8 EPS Ana. |
Dec 2027 12 Rev. Ana. 8 EPS Ana. |
Dec 2028 10 Rev. Ana. 5 EPS Ana. |
Dec 2029 5 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
49.69M
est.
|
126.79M
est.
|
161.61M
est: 160.40M (+0.8%)
|
168.68M
est: 171.35M (-1.6%)
|
175.52M
est: 180.68M (-2.9%)
|
233.11M
est: 234.57M (-0.6%)
|
367.99M
est: 363.96M (+1.1%)
|
491.77M
est: 491.71M (+0.0%)
|
632.76M
est: 633.04M (0.0%)
|
640.07M
est: 656.93M (-2.6%)
|
680.33M
est: 689.96M (-1.4%)
|
828.93M
est: 815.53M (+1.6%)
|
1.04B
est: 1.04B (+0.4%)
|
1.23B
est: 1.25B (-2.0%)
|
1.41B
est: 1.44B (-2.0%)
|
1.95B
est: 1.93B (+0.8%)
|
2.54B
est: 2.54B (0.0%)
|
2.97B
est: 2.97B (+0.1%)
|
3.78B
est: 3.79B (-0.3%)
|
4.56B
est: 4.53B (+0.7%)
|
5.44B
est: 5.40B (+0.7%)
|
6.72B
est: 6.56B (+2.3%)
|
6.71B
est: 6.74B (-0.4%)
|
6.51B
est: 6.72B (-3.1%)
|
6.95B
est: 6.96B (-0.1%)
|
7.30B
est: 7.31B (-0.2%)
|
7.61B
7.44B – 7.74B
+4.2% YoY
|
8.04B
7.53B – 8.40B
+5.7% YoY
|
8.62B
8.60B – 8.65B
+7.2% YoY
|
9.42B
9.01B – 9.71B
+9.3% YoY
|
| EBITDA |
5.02M
est.
|
8.53M
est.
|
17.38M
est: 9.85M (+76.4%)
|
18.97M
est: 16.13M (+17.6%)
|
26.46M
est: 16.87M (+56.8%)
|
40.80M
est: 31.42M (+29.9%)
|
59.24M
est: 51.36M (+15.3%)
|
67.76M
est: 68.68M (-1.3%)
|
80.92M
est: 72.37M (+11.8%)
|
59.21M
est: 53.34M (+11.0%)
|
91.99M
est: 35.50M (+159.1%)
|
140.56M
est: 78.13M (+79.9%)
|
160.80M
est: 135.47M (+18.7%)
|
185.56M
est: 150.32M (+23.4%)
|
224.12M
est: 158.52M (+41.4%)
|
319.96M
est: 219.75M (+45.6%)
|
477.96M
est: 249.20M (+91.8%)
|
518.14M
est: 384.91M (+34.6%)
|
654.71M
est: 566.80M (+15.5%)
|
859.60M
est: 681.16M (+26.2%)
|
1.28B
est: 788.66M (+62.7%)
|
1.75B
est: 845.29M (+106.8%)
|
1.47B
est: 898.90M (+64.0%)
|
1.22B
est: 1.43B (-15.0%)
|
1.38B
est: 1.48B (-6.7%)
|
1.45B
est: 1.56B (-6.8%)
|
1.62B
1.58B – 1.65B
+4.2% YoY
|
1.71B
1.60B – 1.79B
+5.7% YoY
|
1.83B
1.83B – 1.84B
+7.2% YoY
|
2.01B
1.92B – 2.07B
+9.3% YoY
|
| EBIT |
3.45M
est.
|
2.51M
est.
|
4.79M
est: 1.54M (+212.1%)
|
7.33M
est: 5.13M (+42.9%)
|
14.66M
est: 7.70M (+90.4%)
|
27.39M
est: 18.44M (+48.5%)
|
39.39M
est: 46.08M (-14.5%)
|
41.07M
est: 50.23M (-18.2%)
|
44.90M
est: 49.59M (-9.5%)
|
12.79M
est: 43.48M (-70.6%)
|
49.80M
est: 10.71M (+364.9%)
|
87.17M
est: 57.56M (+51.4%)
|
101.90M
est: 110.34M (-7.6%)
|
112.04M
est: 157.53M (-28.9%)
|
132.90M
est: 186.11M (-28.6%)
|
185.85M
est: 259.16M (-28.3%)
|
311.67M
est: 346.28M (-10.0%)
|
305.13M
est: 419.21M (-27.2%)
|
355.30M
est: 508.92M (-30.2%)
|
369.00M
est: 621.49M (-40.6%)
|
798.00M
est: 633.74M (+25.9%)
|
1.36B
est: 679.24M (+99.9%)
|
885.60M
est: 722.32M (+22.6%)
|
552.70M
est: 844.24M (-34.5%)
|
695.30M
est: 873.70M (-20.4%)
|
819.00M
est: 917.56M (-10.7%)
|
955.92M
934.74M – 971.65M
+4.2% YoY
|
1.01B
945.28M – 1.05B
+5.7% YoY
|
1.08B
1.08B – 1.09B
+7.2% YoY
|
1.18B
1.13B – 1.22B
+9.3% YoY
|
| Net Income |
1.10M
est.
|
-502.0K
est.
|
139.0K
est: -2.43M (+105.7%)
|
1.61M
est: 106.8K (+1,410.8%)
|
7.85M
est: 1.69M (+365.1%)
|
12.39M
est: 10.13M (+22.4%)
|
17.51M
est: 19.24M (-9.0%)
|
17.64M
est: 23.57M (-25.2%)
|
17.71M
est: 22.79M (-22.3%)
|
-11.29M
est: 18.37M (-161.4%)
|
23.40M
est: -11.76M (+298.9%)
|
55.41M
est: 27.66M (+100.3%)
|
65.92M
est: 70.67M (-6.7%)
|
72.18M
est: 79.19M (-8.8%)
|
79.10M
est: 82.99M (-4.7%)
|
87.32M
est: 107.96M (-19.1%)
|
174.00M
est: 114.39M (+52.1%)
|
216.77M
est: 203.96M (+6.3%)
|
223.90M
est: 276.10M (-18.9%)
|
195.20M
est: 267.26M (-27.0%)
|
539.40M
est: 215.81M (+149.9%)
|
782.60M
est: 231.31M (+238.3%)
|
610.20M
est: 413.90M (+47.4%)
|
310.30M
est: 325.90M (-4.8%)
|
406.40M
est: 458.33M (-11.3%)
|
475.00M
est: 670.04M (-29.1%)
|
708.00M
649.18M – 766.81M
+5.7% YoY
|
796.45M
690.30M – 902.61M
+12.5% YoY
|
969.83M
904.31M – 1.04B
+21.8% YoY
|
1.03B
968.23M – 1.07B
+5.9% YoY
|
| SGA |
25.57M
est.
|
69.52M
est.
|
80.49M
est: 83.04M (-3.1%)
|
80.93M
est: 86.00M (-5.9%)
|
—
est: 85.30M (-100.0%)
|
107.37M
est: 107.37M (+0.0%)
|
169.48M
est: 166.64M (+1.7%)
|
233.59M
est: 228.26M (+2.3%)
|
301.35M
est: 303.87M (-0.8%)
|
315.39M
est: 314.43M (+0.3%)
|
253.58M
est: 333.57M (-24.0%)
|
—
est: 389.94M (-100.0%)
|
—
est: 515.23M (-100.0%)
|
11.57M
est: 8.29M (+39.5%)
|
15.22M
est: 9.54M (+59.5%)
|
30.42M
est: 12.84M (+137.0%)
|
38.36M
est: 16.83M (+128.0%)
|
48.36M
est: 19.69M (+145.6%)
|
89.90M
est: 25.15M (+257.5%)
|
52.50M
est: 30.06M (+74.7%)
|
38.20M
est: 35.82M (+6.6%)
|
60.30M
est: 43.54M (+38.5%)
|
39.40M
est: 44.72M (-11.9%)
|
73.60M
est: 35.16M (+109.3%)
|
—
est: 36.39M (-100.0%)
|
—
est: 38.21M (-100.0%)
|
39.81M
38.93M – 40.46M
+4.2% YoY
|
42.06M
39.37M – 43.93M
+5.7% YoY
|
45.08M
44.94M – 45.21M
+7.2% YoY
|
49.27M
47.12M – 50.79M
+9.3% YoY
|
| EPS |
0.12
est.
|
-0.14
est.
|
0.00
est: 0.01 (-90.9%)
|
0.01
est: 0.18 (-93.3%)
|
0.06
est: 0.42 (-86.1%)
|
0.09
est: 1.10 (-91.7%)
|
0.13
est: 1.19 (-89.1%)
|
0.13
est: 1.27 (-89.8%)
|
0.07
est: 1.04 (-93.4%)
|
-0.08
est: -0.51 (+84.4%)
|
0.11
est: 1.37 (-91.9%)
|
0.31
est: 2.91 (-89.4%)
|
0.37
est: 4.58 (-91.9%)
|
0.35
est: 5.49 (-93.6%)
|
0.52
est: 6.12 (-91.5%)
|
0.57
est: 0.79 (-27.7%)
|
0.87
est: 1.06 (-18.3%)
|
1.05
est: 1.21 (-13.6%)
|
1.26
est: 1.52 (-17.3%)
|
1.10
est: 1.69 (-34.9%)
|
2.90
est: 2.85 (+1.9%)
|
4.09
est: 4.64 (-11.9%)
|
3.17
est: 3.56 (-10.9%)
|
1.61
est: 1.69 (-4.7%)
|
2.13
est: 3.04 (-29.9%)
|
2.64
est: 3.56 (-25.8%)
|
3.76
3.47 – 4.10
+5.6% YoY
|
4.38
3.69 – 4.83
+16.6% YoY
|
5.12
4.84 – 5.54
+16.7% YoY
|
5.49
5.18 – 5.71
+7.3% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | B | 3/5 | 4/5 | 4/5 | 4/5 | 1/5 | 2/5 | 2/5 |
| 2026-05-28 | B | 3/5 | 4/5 | 4/5 | 4/5 | 1/5 | 2/5 | 2/5 |
| 2026-05-27 | B | 3/5 | 4/5 | 4/5 | 4/5 | 1/5 | 2/5 | 2/5 |
| 2026-05-26 | B | 3/5 | 4/5 | 4/5 | 4/5 | 1/5 | 2/5 | 2/5 |
| 2026-05-25 | B | 3/5 | 4/5 | 4/5 | 4/5 | 1/5 | 2/5 | 2/5 |
| 2026-05-22 | B | 3/5 | 4/5 | 4/5 | 4/5 | 1/5 | 2/5 | 2/5 |
| 2026-05-21 | B | 3/5 | 4/5 | 4/5 | 4/5 | 1/5 | 2/5 | 2/5 |
| 2026-05-20 | B | 3/5 | 4/5 | 4/5 | 4/5 | 1/5 | 2/5 | 2/5 |
| 2026-05-19 | B | 3/5 | 4/5 | 4/5 | 4/5 | 1/5 | 2/5 | 2/5 |
| 2026-05-18 | B | 3/5 | 4/5 | 4/5 | 4/5 | 1/5 | 2/5 | 2/5 |
| 2026-05-15 | B | 3/5 | 4/5 | 4/5 | 4/5 | 1/5 | 2/5 | 2/5 |
| 2026-05-14 | B | 3/5 | 4/5 | 4/5 | 4/5 | 1/5 | 2/5 | 2/5 |
| 2026-05-13 | B | 3/5 | 4/5 | 4/5 | 4/5 | 1/5 | 2/5 | 2/5 |
| 2026-05-12 | B | 3/5 | 4/5 | 4/5 | 4/5 | 1/5 | 2/5 | 2/5 |
| 2026-05-11 | B | 3/5 | 4/5 | 4/5 | 4/5 | 1/5 | 2/5 | 2/5 |
| 2026-05-08 | B | 3/5 | 4/5 | 4/5 | 4/5 | 1/5 | 2/5 | 2/5 |
| 2026-05-07 | B | 3/5 | 4/5 | 4/5 | 4/5 | 1/5 | 2/5 | 2/5 |
| 2026-05-06 | B | 3/5 | 4/5 | 4/5 | 4/5 | 1/5 | 2/5 | 2/5 |
| 2026-05-05 | B+ | 3/5 | 4/5 | 4/5 | 4/5 | 1/5 | 3/5 | 2/5 |
| 2026-05-04 | B+ | 3/5 | 4/5 | 4/5 | 4/5 | 1/5 | 3/5 | 2/5 |
| 2026-04-30 | B+ | 3/5 | 4/5 | 4/5 | 4/5 | 1/5 | 3/5 | 2/5 |
| 2026-04-29 | B+ | 3/5 | 4/5 | 4/5 | 4/5 | 1/5 | 3/5 | 2/5 |
| 2026-04-28 | B+ | 3/5 | 4/5 | 4/5 | 4/5 | 1/5 | 3/5 | 2/5 |
| 2026-04-27 | B+ | 3/5 | 4/5 | 4/5 | 4/5 | 1/5 | 3/5 | 2/5 |
| 2026-04-24 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-04-23 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-22 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-21 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-20 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-17 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-16 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 1/5 | 2/5 | 2/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
1.53B
OE per share TTM
7.98
Owner's Yield
13.59%
Maintenance CapEx ratio
180.35%
Maint CapEx / Avg PPE
33.5%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
Held by 287 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | iShares EURO STOXX Mid UCITS ETF DJMC.L | 0.98% | 6.26M | 0.40% |
| 2 | BMO Low Volatility International Equity ETF ZLI.TO | 0.81% | 1.63M | 0.45% |
| 3 | iShares MSCI EMU Mid Cap UCITS ETF EUR EMUM.L | 0.70% | 4.35M | 0.49% |
| 4 | Invesco STOXX Europe 600 Optimised Health Care UCITS ETF SC0T.DE | 0.59% | 79.4K | 0.20% |
| 5 | Amundi MSCI EMU SRI Climate Paris Aligned UCITS ETF DR (C) SRHE.L | 0.57% | 772.2K | 0.18% |
| 6 | iShares MSCI Europe Mid-Cap Equal Weight UCITS ETF IEFS.L | 0.50% | 193.9K | 0.25% |
| 7 | iShares MSCI Europe Health Care Sector UCITS ETF ESIH.L | 0.49% | 4.94M | 0.18% |
| 8 | State Street SPDR MSCI Europe Health Care UCITS ETF HLTH.L | 0.49% | 3.31M | 0.18% |
| 9 | iShares STOXX Europe Mid 200 UCITS ETF (DE) EXSD.DE | 0.48% | 3.22M | 0.20% |
| 10 | Xtrackers MSCI Europe Health Care Screened UCITS ETF 1C XSDR.L | 0.48% | 1.82M | 0.17% |
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
EBIT / Employee
12.7K
Shares Outstanding
174.71M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Gilles G. Martin | Chairman of the Board & Chief Executive Officer | 3M | — |
| Valerie Hanote | Executive Director | 462.0K | female |
| Francois Vigneau | Senior Vice President of Food & Feed Testing - Western Europe | — | male |
| Gabriel Julia | Senior Vice President of Clinical Diagnostics Europe | — | male |
| Joachim Reichelt | Senior Vice President of Food & Feed Testing Europe | — | male |
| Laurent Lebras | Group Administration & Chief Financial Officer | — | male |
| Timothy S. Oostdyk | Executive Vice President of BioPharma, Genomics & Agrosciences Services North America | — | — |
| Bernard Wang | Head of Investor Relations | — | male |
| Yvoine Remy | Senior Vice President of Environment Testing Europe | — | female |
| David W. Bryant | Senior Vice President of Strategic Business Development North America | — | male |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for ERF.PA
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
